Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$81.15 -0.6%	$42.55	$4.77 ▼ $81.95	$6.13B	0.56	662,587 shs	39,429 shs
AXSM Axsome Therapeutics	$121.13 -0.5%	$107.80	$75.56 ▼ $139.13	$6.07B	0.51	762,846 shs	199 shs
RNA Avidity Biosciences	$48.90 +0.7%	$37.05	$21.51 ▼ $56.00	$6.28B	0.95	1.84 million shs	590 shs
WVE WAVE Life Sciences	$9.86 -0.7%	$8.18	$5.04 ▼ $16.74	$1.57B	-0.95	1.33 million shs	16,871 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+2.78%	+9.69%	+16.96%	+1,260.67%	+565.91%
AXSM Axsome Therapeutics	-0.09%	+3.94%	+21.25%	+16.04%	+37.68%
RNA Avidity Biosciences	+1.59%	+8.78%	+35.13%	+56.81%	+11.35%
WVE WAVE Life Sciences	-1.49%	+1.74%	+19.35%	+63.32%	+77.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX Abivax	2.6989 of 5 stars	3.6	3.0	0.0	3.0	0.8	0.6
AXSM Axsome Therapeutics	4.8306 of 5 stars	4.5	1.0	4.5	4.0	4.2	0.6
RNA Avidity Biosciences	3.1495 of 5 stars	4.5	2.0	0.0	4.0	0.8	0.0
WVE WAVE Life Sciences	4.78 of 5 stars	4.5	1.0	4.8	3.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.13	Buy	$92.33	13.78% Upside
AXSM Axsome Therapeutics	3.07	Buy	$178.00	46.96% Upside
RNA Avidity Biosciences	3.06	Buy	$67.00	37.01% Upside
WVE WAVE Life Sciences	2.93	Moderate Buy	$20.27	105.52% Upside

Current Analyst Ratings Breakdown

Latest WVE, RNA, AXSM, and ABVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RNA Avidity Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00
8/8/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$59.00 ➝ $62.00
8/8/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
8/4/2025	WVE WAVE Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
7/31/2025	WVE WAVE Life Sciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $21.00
7/29/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $112.00
7/28/2025	WVE WAVE Life Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$24.00
7/23/2025	ABVX Abivax	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$74.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
AXSM Axsome Therapeutics	$385.69M	15.67	N/A	N/A	$1.46 per share	82.96
RNA Avidity Biosciences	$10.90M	577.15	N/A	N/A	$9.27 per share	5.28
WVE WAVE Life Sciences	$108.30M	14.49	N/A	N/A	$0.88 per share	11.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	42.95	N/A	-49.88%	-283.22%	-33.06%	11/11/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.56	N/A	N/A	N/A	-4,247.77%	-33.45%	-30.22%	11/6/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.90	N/A	N/A	N/A	N/A	-78.45%	-41.51%	11/11/2025 (Estimated)

Latest WVE, RNA, AXSM, and ABVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
7/30/2025	Q2 2025	WVE WAVE Life Sciences	-$0.29	-$0.31	-$0.02	-$0.31	$11.52 million	$8.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	1.25	1.25
AXSM Axsome Therapeutics	1.66	1.57	1.51
RNA Avidity Biosciences	N/A	9.26	9.26
WVE WAVE Life Sciences	N/A	2.56	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
AXSM Axsome Therapeutics	81.49%
RNA Avidity Biosciences	N/A
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
AXSM Axsome Therapeutics	22.30%
RNA Avidity Biosciences	3.83%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	75.57 million	N/A	Not Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
RNA Avidity Biosciences	190	128.65 million	123.73 million	Optionable
WVE WAVE Life Sciences	240	159.14 million	120.98 million	Optionable

WVE, RNA, AXSM, and ABVX Headlines

Recent News About These Companies

WAVE Life Sciences Ltd. $WVE Shares Purchased by Charles Schwab Investment Management Inc.

August 29 at 3:14 AM | marketbeat.com

WAVE Life Sciences Ltd. $WVE Shares Acquired by Affinity Asset Advisors LLC

August 28 at 9:02 AM | marketbeat.com

WAVE Life Sciences Ltd. $WVE Stock Position Raised by Martingale Asset Management L P

August 28 at 4:51 AM | marketbeat.com

Gregory Verdine Sells 10,000 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

August 27 at 7:20 AM | insidertrades.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from Analysts

August 26 at 2:13 AM | marketbeat.com

WAVE Life Sciences Ltd. $WVE Shares Sold by Maven Securities LTD

August 23, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $1.02 Million Stock Position in WAVE Life Sciences Ltd. $WVE

August 19, 2025 | marketbeat.com

29,572 Shares in WAVE Life Sciences Ltd. (NASDAQ:WVE) Bought by Wealthedge Investment Advisors LLC

August 18, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Trading Up 7.8% - Still a Buy?

August 17, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells $85,192.70 in Stock

August 15, 2025 | marketbeat.com

Wave Life Sciences moved to not rated at JPMorgan

August 15, 2025 | msn.com

Insider Selling: WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells 9,670 Shares of Stock

August 14, 2025 | insidertrades.com

Wave Life Sciences Shareholders Approve Key Proposals

August 11, 2025 | msn.com

Wave Life Sciences Earnings Call: Clinical Advances Amid Financial Challenges

August 9, 2025 | theglobeandmail.com

Ken Takanashi Sells 4,872 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) Stock

August 8, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Ken Takanashi Sells 4,872 Shares

August 8, 2025 | insidertrades.com

WAVE Life Sciences (NASDAQ:WVE) Now Covered by Canaccord Genuity Group

August 5, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Holdings Trimmed by TD Asset Management Inc

August 5, 2025 | marketbeat.com

Wave Life Sciences is a new Buy at Canaccord Genuity on near-term catalysts

August 5, 2025 | msn.com

Canaccord Genuity Initiates Coverage of Wave Life Sciences (WVE) with Buy Recommendation

August 5, 2025 | msn.com

B. Riley Reduces Earnings Estimates for WAVE Life Sciences

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

WVE, RNA, AXSM, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

$81.15 -0.49 (-0.60%)

As of 09:47 AM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Axsome Therapeutics NASDAQ:AXSM

$121.12 -0.63 (-0.51%)

As of 09:47 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Avidity Biosciences NASDAQ:RNA

$48.90 +0.32 (+0.66%)

As of 09:48 AM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

WAVE Life Sciences NASDAQ:WVE

$9.86 -0.07 (-0.69%)

As of 09:47 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time